Skip to main content Skip to section navigation Skip to footer
Alopexx
  • Home
  • About
    • Overview
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Antimicrobial Resistance
  • Neuroinflammation
  • Therapeutic Solutions
    • Overview
    • Immune Therapy for Microbial Diseases
    • Immune Therapy for Neuroinflammation
    • PNAG Platform
    • Presentations & Publications
  • Pipeline
    • Overview
    • Monoclonal Antibody F598
    • Monoclonal Antibody AB0411
    • Vaccine AV0328
    • Vaccine AV0407
    • Potential of Targeting PNAG
  • In the News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 10, 2024 9:00am EDT

Alopexx Announces Collaboration with Bharat Biotech for the Development and Commercialization of Broad-Spectrum Anti-Microbial Vaccine AV0328

Sep 06, 2024 9:00am EDT

Alopexx Announces Investment from Biotech Consortia, Inc.

Oct 20, 2021 8:30am EDT

Alopexx Expands Leadership Team with Appointment of Thomas T. Thomas as Chief Financial Officer

rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© Alopexx. All Rights Reserved.
Privacy Policy Disclaimer Sitemap